(3) AKT3 may contribute to endocrine therapy resistance of ErbB2(+) BC cells with aggressive behavior [47], because AKT3 expression and activity are elevated in ErbB2(+) TNBC cells and tamoxifen-resistant BC cells, and activated AKT3 decreases the sensitivity of ErbB2(+) BC cells to tamoxifen (an endocrine therapy used to treat hormone receptor-positive BC). Here, ERBB2 is linked to breast cancer.